Under the new guidelines of the National Institute for Health and Clinical Excellence (NICE), it has been said the bevacizumab (Avastin) should not be given in the advanced ovarian cancer. It has happened in those cases where the cancer has come back in six months of platinum-based chemotherapy.
According to Sir Andrew Dillon, NICE's chief executive, evidence proves that the high price of the bevacizumab is not justified. Frances Reid, its director of public affairs and communications, said that the women would be shattered by the decision. He said that there is uncertainty if the drug would be available to women by the Cancer Drugs Fund and some may die while waiting for it.
As far as ovarian cancer is concerned, it repeats for every 55% to 75% of ovarian cancer sufferers whose tumors positively responded to chemotherapy in the beginning. According to Roche, the women with the ovarian cancer can add four months of extra life. He also added to his statement that 3,850 to 5,250 women might be helped if the Avastin is available at NHS.
Looking at the number of cases of more than 1300 Australian women who are diagnosed with ovarian cancer each year and 800 women out of them who die after battling with the disease, the guidelines hold significant implications.